![](\"https:\/\/mms.businesswire.com\/media\/20260708430207\/en\/2446006\/5\/Latigo_logo.jpg\"){kind=logo}
<\/a><\/a>\n\u201cTodd\u2019s extensive commercial expertise with launching numerous innovative biopharmaceutical products comes at an important time for Latigo,\u201d said Nima Farzan, CEO of Latigo. \u201cWe are excited to add his strategic insight and proven track record of commercial execution to our board.\u201d<\/p>
\n\u201cTodd is an accomplished biopharmaceutical executive with deep expertise in commercialization, business development and corporate strategy,\u201d said Tim Walbert, chair of Latigo\u2019s board of directors. \u201cHis experience bringing innovative medicines to patients and building high-performing organizations will be invaluable.\u201d<\/p>
\n\u201cLatigo has built an impressive pipeline of non-opioid drug product candidates,\u201d said Mr. Smith. \u201cI am excited to join the board and work with the management team to support the Company on its mission to deliver innovative, non-opioid pain therapies.\u201d<\/p>
\nAbout Todd Smith<\/b><\/p>
\nMr. Smith is chief executive officer (CEO) of Corium, a commercial-stage biopharmaceutical company focused on neuroscience. He brings more than 30 years of leadership experience spanning commercial operations, business development, and executive management across the biopharmaceutical industry.<\/p>
\nPrior to joining Corium, Mr. Smith served as CEO of Valinor Pharma, Iroko Pharmaceuticals, Zyla Life Sciences, and Assertio Therapeutics. Earlier in his career, he served as chief commercial officer (CCO) and head of business development at Horizon Therapeutics and CCO at Tolmar Pharmaceuticals, following commercial leadership roles at Abbott Labs and Fenwal. Mr. Smith currently serves on the boards of BVI Medical, Quetzal Therapeutics and Corium. He earned a B.A. in political science from Norwich University.<\/p>
\nAbout Latigo Biotherapeutics<\/b><\/p>
\nLatigo Biotherapeutics is a private clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction, with the goal to provide effective, rapid-acting pain relief. Latigo is supported by leading investors, including Westlake Village BioPartners, Foresite Capital, 5AM Ventures and Blue Owl Capital. Latigo's lead program is LTG-001, an oral, selective NaV1.8 inhibitor in development to treat acute pain. For more information, please visit www.latigobio.com<\/a> or follow us on LinkedIn<\/a>.<\/p> \nInvestor Contact:<\/b>